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Effect of Venlafaxine on Swimming Behavior of Fathead Minnows  
After 24-hour Exposure 
 
 
ABSTRACT 
 
Depression is a mood altering disorder that affects 350 million people globally. To combat the prevalence 
of depression, antidepressants are prescribed to restore the balance of neurochemicals in the brain. 
Venlafaxine, with over 15 million prescriptions in the US in 2013, is a serotonin and norepinephrine 
reuptake inhibitor (SNRI) antidepressant. Serotonin and norepinephrine are associated with alertness, 
energy, and happiness, thus increasing levels in the brain promotes improved mood in patients. However, 
investigating the environmental release and effects of venlafaxine is important to determine potential 
adverse effects on non-target organisms. Venlafaxine, as well as other pharmaceuticals, enters freshwater 
ecosystems from wastewater effluent recorded at µg/L concentrations because wastewater treatment 
methods do not completely remove excreted venlafaxine. Removal efficiencies at the Ithaca Area 
Wastewater Treatment Facility (IAWWTF) for venlafaxine were reported at 0% in May 2015. IAWWTF 
receives above average antidepressant loads partly due to the two local universities in the area. The 
IAWWTF discharges effluent into the southern portion of Cayuga Lake, exposing freshwater ecosystems 
and local recreational waters to the antidepressant. Our study aims to test the effects of venlafaxine on 
juvenile fathead minnow (Pimephales promelas) swimming patterns at an environmentally relevant 
concentration of 0.2 µg/L in addition to concentrations of 2 and 20 µg/L for 24 hours. EthoVision video 
tracking software was used after the dosage period to determine altered swimming activity, such as 
twitching, velocity, thigmotaxis, schooling, location-based heat maps. 
 
